Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Sethi

Showing results (121-130 of 206) with videos related to

Pageof 21
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|July 16, 2011
A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodologyRobert Wilson, Antonio Anzueto, Marc Miravitlles, et al.
The European Respiratory Journal|December 3, 2011
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL resultsRobert Wilson, Antonio Anzueto, Marc Miravitlles, et al.
BMC Pulmonary Medicine|August 30, 2025
Progression from GOLD A/B to GOLD E: a claims analysis of patients with COPD newly initiating inhaled therapyTrishul Siddharthan, Sanjay Sethi, Emily Wan, et al.
Lung|April 17, 2016
A Sputum Proteomic Signature That Associates with Increased IL-1β Levels and Bacterial Exacerbations of COPDGautam Damera, Tuyet-Hang Pham, Jianchun Zhang, et al.
Proceedings (Baylor University. Medical Center)|December 31, 2021
Imaging findings in invasive rhino-orbito-cerebral mucormycosis in post-COVID-19 patientsGunjan Jindal, Aaftab Sethi, Kanika Bhargarva, et al.
Pulmonary Pharmacology & Therapeutics|June 2, 2019
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trialsJames F Donohue, Gregory Feldman, Sanjay Sethi, et al.
American Journal of Respiratory and Critical Care Medicine|September 4, 2010
Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diaryNancy K Leidy, Teresa K Wilcox, Paul W Jones, et al.
Annals of the American Thoracic Society|August 23, 2014
Infections in "noninfectious" lung diseasesMeghan E Fitzpatrick, Sanjay Sethi, Charles L Daley, et al.
American Journal of Respiratory and Critical Care Medicine|January 19, 2008
Pseudomonas aeruginosa in chronic obstructive pulmonary diseaseTimothy F Murphy, Aimee L Brauer, Karen Eschberger, et al.
Clinical and Vaccine Immunology : CVI|March 27, 2009
Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalisEric R LaFontaine, Lauren E Snipes, Brian Bullard, et al.
Pageof 21

Showing results (121-130 of 206) with videos related to

Sort By:
Pageof 21
International Journal of Chronic Obstructive Pulmonary Disease|July 16, 2011
A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodologyRobert Wilson, Antonio Anzueto, Marc Miravitlles, et al.
The European Respiratory Journal|December 3, 2011
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL resultsRobert Wilson, Antonio Anzueto, Marc Miravitlles, et al.
BMC Pulmonary Medicine|August 30, 2025
Progression from GOLD A/B to GOLD E: a claims analysis of patients with COPD newly initiating inhaled therapyTrishul Siddharthan, Sanjay Sethi, Emily Wan, et al.
Lung|April 17, 2016
A Sputum Proteomic Signature That Associates with Increased IL-1β Levels and Bacterial Exacerbations of COPDGautam Damera, Tuyet-Hang Pham, Jianchun Zhang, et al.
Proceedings (Baylor University. Medical Center)|December 31, 2021
Imaging findings in invasive rhino-orbito-cerebral mucormycosis in post-COVID-19 patientsGunjan Jindal, Aaftab Sethi, Kanika Bhargarva, et al.
Pulmonary Pharmacology & Therapeutics|June 2, 2019
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trialsJames F Donohue, Gregory Feldman, Sanjay Sethi, et al.
American Journal of Respiratory and Critical Care Medicine|September 4, 2010
Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diaryNancy K Leidy, Teresa K Wilcox, Paul W Jones, et al.
Annals of the American Thoracic Society|August 23, 2014
Infections in "noninfectious" lung diseasesMeghan E Fitzpatrick, Sanjay Sethi, Charles L Daley, et al.
American Journal of Respiratory and Critical Care Medicine|January 19, 2008
Pseudomonas aeruginosa in chronic obstructive pulmonary diseaseTimothy F Murphy, Aimee L Brauer, Karen Eschberger, et al.
Clinical and Vaccine Immunology : CVI|March 27, 2009
Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalisEric R LaFontaine, Lauren E Snipes, Brian Bullard, et al.
Pageof 21